Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A001: Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors

Yu Akazawa, Ako Hosono, Toshiaki Yoshikawa, Hide Kaneda, Junichi Hara, Yoshiaki Kinoshita, Kenichi Kohashi, Atsushi Manabe, Yoko Shioda, Kayoko Shoda, Manami Shimomura, Shoichi Mizuno, Yasunari Nakamoto and Tetsuya Nakatsura
Yu Akazawa
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ako Hosono
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiaki Yoshikawa
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hide Kaneda
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junichi Hara
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiaki Kinoshita
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenichi Kohashi
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Manabe
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoko Shioda
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayoko Shoda
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manami Shimomura
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoichi Mizuno
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasunari Nakamoto
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuya Nakatsura
National Cancer Center, Kashiwa, Japan; National Cancer Center Hospital, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan; Kyushu University Hospital, Fukuoka, Japan; St Luke's International Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Fukui University, Fukui, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A001 Published February 2019
  • Article
  • Info & Metrics
Loading
Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY

Abstract

Recently, the aggressive intervention of multidisciplinary therapy has resulted in improving the life prognosis of pediatric solid tumors. However, in the pediatric patients with metastatic or refractory solid tumors, the prognosis remains poor. Additionally, various critical, late complications could continue to occur. Therefore, the development of novel, effective therapy is urgently required. Immunotherapy could be the one of effective therapeutic strategy for pediatric solid tumors. Actually, the KOC1, FOXM1, and KIF20A might be capable of being an ideal target of anticancer immunotherapy against pediatric solid tumors that highly had expression of these cancer antigens. In this nonrandomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of NCCV cocktail 1 vaccine, a cocktail of cancer peptides derived from KOC1, FOXM1, and KIF20A, in patients with pediatric solid tumors. Experimental Design: Twelve patients with refractory pediatric solid tumors, including 3 patients with neuroblastoma, 2 patients with Ewing’s sarcoma, 5 patients with rhabdomyosarcoma, and 2 patients with osteosarcoma, underwent NCCV cocktail 1 vaccination (intradermal injections every a week). In 9 enrolled patients, the histologic expression of KOC1, FOXM1, and KIF20A before vaccination were evaluated using tissue specimen obtained from biopsy or surgery. The primary endpoint was the safety of NCCV cocktail 1 vaccination. The secondary endpoints were immune response, as measured by in vivo and in vitro interferon (IFN)-r enzyme-linked immunospot (ELISPOT) assay and Dextramer assay, and the clinical outcomes of tumor response and progression free survival (PFS).Results:No dose-limiting toxicity (DLT) was observed in this trial, and we suggested that NCCV cocktail 1 vaccination was well-tolerated. Of nine patients, 6 patients (66.7%), 6 patients (66.7%), and 7 patients (77.8%), exhibited positive expression of KOC1, FOXM1, and KIF20A before vaccination, respectively. Of eleven patients, 4 patients (36.4%), 8 patients (72.7%), and 5 patients (45.5%) were induced peptide-specific CTL response of KOC, FOXM1, and KIF20A by NCCV cocktail 1 vaccine, respectively. Also, 4 patients showed stable disease after 8 weeks, and 2 patients showed during of remission for more than 11 months after second complete remission. Additionally, patients with high peptide-specific CTL frequencies of all KOC, FOXM1, and KIF20A (n=4) had better PFS than those with low frequencies (n=7) by Kaplan-Meier analysis (log-rank test, P =0.019). By Cox proportional hazard models, univariate and multivariate analysis indicated that only induction of peptide specific CTL in all of these three antigens was independent factor related to PFS (P = 0.039; HR = 5.60; 95% CI 1.09-28.91, P = 0.050; HR = 6.00; 95% CI 1.00-36.32, respectively). Conclusions:The results of this trial demonstrated that the NCCV cocktail 1 vaccine was safe and had ability to induce some degree of immune response, which could result in the benefit for preventing the recurrence of pediatric solid tumors, especially after a second complete remission.

Citation Format: Yu Akazawa, Ako Hosono, Toshiaki Yoshikawa, Hide Kaneda, Junichi Hara, Yoshiaki Kinoshita, Kenichi Kohashi, Atsushi Manabe, Yoko Shioda, Kayoko Shoda, Manami Shimomura, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura. Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A001.

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 7 (2 Supplement)
February 2019
Volume 7, Issue 2 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A001: Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A001: Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors
Yu Akazawa, Ako Hosono, Toshiaki Yoshikawa, Hide Kaneda, Junichi Hara, Yoshiaki Kinoshita, Kenichi Kohashi, Atsushi Manabe, Yoko Shioda, Kayoko Shoda, Manami Shimomura, Shoichi Mizuno, Yasunari Nakamoto and Tetsuya Nakatsura
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A001; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A001: Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors
Yu Akazawa, Ako Hosono, Toshiaki Yoshikawa, Hide Kaneda, Junichi Hara, Yoshiaki Kinoshita, Kenichi Kohashi, Atsushi Manabe, Yoko Shioda, Kayoko Shoda, Manami Shimomura, Shoichi Mizuno, Yasunari Nakamoto and Tetsuya Nakatsura
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A001; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement